Due to the necessity to evaluate the evolution of the global pandemic, the development of detection test is being prioritized not only in patients but also in the environment.
In this regard, is very important to demonstrate the reliability of the results obtained, and the PT Schemes are a fundamental tool to evaluate the technical competence of the assays developed.
ielab will open very soon the registration for a PT Scheme about the SARS-CoV-2 (COVID-19) detection by means RT-qPCR.
Samples employed will be synthetic, no-infectious, and will content RNA from several SARS-CoV-2 target genes (E, N, ORF1ab, RdRP y S), which will allow evaluating the complete virus detection methodology. The fields of application are:
Results will be reported qualitatively (Presence/Absence) and a final report will be published after studing the results.